Esperion Therapeutics Surges Amid Reports of Acquisition Talks with Otsuka

Esperion Therapeutics' stock surged 20% amid speculation about a potential takeover by Otsuka. Sources suggest the Japanese company is in talks to acquire full rights or possibly all of Esperion, although no details have been confirmed.

Esperion Therapeutics (NASDAQ:ESPR) saw its stock price jump by 20% on July 2, 2025, amidst rumors of a potential takeover by Otsuka (OTCPK:OTSKY). The rumors suggest that Otsuka is in talks to acquire full rights or possibly all of Esperion, with a potential deal valued around $900 million [1]. The speculation comes as Esperion's bempedoic acid is nearing approval in Japan.

The surge in Esperion's stock price is attributed to the rumors, which have sparked investor interest and buying activity. The company's market capitalization stands at $263 million, with 12% short interest [1]. Esperion is set to report its Q2 2025 financial results on August 5, 2025, followed by a management webcast [3].

In the first quarter of 2025, Esperion reported a 63% year-over-year growth in total revenue, reaching $65 million. The company's US net product revenue increased by 41% year-over-year to $34.9 million, driven by expanded label and commercial initiatives [2]. Despite the positive financial performance, Esperion faced challenges such as a flat lipid market in the US and changes in Medicare Part D, which impacted Q1 2025 product revenue growth [2].

Esperion's focus on developing new medicines for patients with unmet needs in cardiovascular disease has positioned it as a leader in the biopharmaceutical field. The company's next-generation program on ATP citrate lyase inhibitors (ACLYi) underscores its commitment to innovation and addressing unmet medical needs [3].

However, the lack of specific financial forecasts or guidance ahead of the Q2 2025 results announcement may raise concerns among investors regarding Esperion's financial health. The company's insiders have been active in selling shares, with 12 sales in the past 6 months [3]. Additionally, there has been a significant increase in hedge fund positions, with 76 institutional investors adding shares and 82 decreasing their positions in the most recent quarter [3].

References:
[1] https://seekingalpha.com/news/4471632-esperion-therapeutics-soars-amid-vague-takeover-speculation
[2] https://www.gurufocus.com/news/3002759/rumors-propel-esperion-espr-stock-up-19-in-afternoon-trading-espr-stock-news
[3] https://www.quiverquant.com/news/Esperion+to+Announce+Second+Quarter+2025+Financial+Results+on+August+5%2C+2025